Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis

Inclusion Criteria:

1. Confirmed gMG diagnosis supported by the following:

• Documented report of positive serology testing for either AChR antibodies orMuSK antibodies at screening AND at least one of the following:

• History of abnormal neuromuscular transmission test demonstrated by repetitivenerve stimulation or single-fiber electromyography

• History of positive acetylcholinesterase inhibitor test

• Improvement in MG signs on an oral acetylcholinesterase inhibitor as assessedby the treating physician

2. MGFA Class III-IVa (gMG) at screening

3. Treatment-resistant gMG as defined by: MG-ADL score ≥ 6 at screening despiteadequate treatment trials with at least two different non-steroidalimmunosuppressive drugs given at adequate doses and duration of therapy.

4. If on chronic corticosteroids, the ability and willingness to taper to a maximumdose of 10 mg prednisolone daily or equivalent at least one week beforeleukapheresis

5. If treated with cholinesterase inhibitors, patients must be on a stable dose for atleast two weeks prior to screening

Exclusion Criteria:

1. Exclusively ocular myasthenia gravis (MGFA I), mild symptoms (MGFA II), or severebulbar disease or MG crisis, MGFA Class IVb or V at screening

2. History of bone marrow/hematopoietic stem cell or solid organ transplantation.

3. Clinically significant active, opportunistic, chronic or recurrent infection (including positive for hepatitis B or hepatitis C) confirmed by clinical evidence,imaging, or positive laboratory tests one month prior to leukapheresis

4. Other uncontrolled disease states, such as asthma, or inflammatory bowel disease,where flares are commonly treated with oral or parenteral corticosteroids, atscreening

5. Participants with a known immunodeficiency syndrome (AIDS, hereditary immunedeficiency, drug induced immune deficiency), or tested positive for HIV antibody, atscreening

6. Prior treatment with anti-CD19 therapy, adoptive T cell therapy or any prior genetherapy product (e.g. CAR-T cell therapy).

Other protocol-defined inclusion/exclusion criteria may apply